The PennZone

PHILADELPHIA, Oct. 16, 2020 /PRNewswire/ -- Enterin, Inc., a privately held, CNS-focused pharmaceutical company based in Philadelphia and developing novel compounds to treat neurodegenerative diseases, announces the appointment of David McCullough as Chief Executive Officer.

With over 30 years of pharma/biotech experience, Mr. McCullough is a demonstrated strategic, creative, and accomplished leader. With executive and board director experience in startup and established companies, David brings expertise in both the private and public sector. He has a deep understanding of drug development, clinical and regulatory strategy, commercial, finance, IP, manufacturing and operations. Mr. McCullough has a proven track record of building highly skilled, energetic, cross-functional teams both domestically and globally. He has strong experience moving products from early development to launch, including orphan drugs and billion-dollar brands. At Merck, he played a lead role in the $13.5B acquisition of Serono Biotech, and he was honored by the Merck family as a top contributor in corporate development. Additionally, Mr. McCullough has held leadership positions in Allergopharma/EMD Serono and BioCryst. He is interested in Enterin as he has a personal passion for the neurodegenerative therapeutic area and the patient population that can be served with better therapeutic outcomes. "I am thrilled to have the opportunity to join this team that is pioneering the science behind truly innovative approaches in the treatment of neurodegenerative diseases," says McCullough.

More on The PennZone

• SnapTax Launches AI-Powered Tax Planning Platform for Freelancers and 1099 Workers — Now Free for 90 Days
• A.M. Logging Highlights Essential Landscaping Supplies for Spring Projects in Central Pennsylvania
• Congressional Roundtable Exposes Mental Health Crisis: More Spending and Treatment, Worse Results – CCHR Demands Accountability
• Attorney Joseph C. Kreps Files Lawsuit to Stop Alabama State Board of Pharmacy's Unlawful "Revenue-First" Rulemaking
• NAIDOC Week Australia 2026 | 50 Years Deadly - Celebrates Culture, Resilience, and Global Connection

Enterin's founders and chairmen, Michael Zasloff, MD, PhD and Denise Barbut MD, FRCP reciprocated the sentiment. They said, "We are delighted that David has agreed to join Enterin. His extensive experience in the pharmaceutical industry will supplement the scientific and medical expertise of the existing management team."

About Enterin Inc.

Enterin Inc. is the first company to develop novel compounds that repair the dysfunctional gut-brain axis in patients with neurodegenerative diseases. Enterin Inc. is pioneering the medical community's understanding of the link between infections, dysfunction of the enteric nervous system (ENS) of the gut and the early onset and chronic progression of neurodegenerative disease. The lead compound, ENT-01, displaces membrane-bound alpha-synuclein (αS) aggregates from nerve cells in the ENS and improves neural signaling between the gut and the brain in preclinical models of Parkinson's disease. Enterin Inc. is now progressing ENT-01 through clinical trials in an attempt to reverse the neurologic symptoms of Parkinson's disease.

More on The PennZone

• Solo Researcher Builds Three Novel AI Architectures From Scratch, Including Post-Transformer Model
• JBlair Communications Launches "NextLevel Spotlight" to Elevate High School/Collegiate Athletes
• R&B Artist Mike Davis Announces Debut Full-Length Album Full Circle, Releasing April 7
• Aurelius Dunbar Earns Prestigious NWCA NCAA Div. I Scholar All-American Honors for 2025-2026 Season
• Second Annual "Autism In Bloom" Event By D&D Journey Promotes Autism Awareness Month

For more information, please visit www.enterininc.com.

Contact
Enterin Inc.
[email protected]

Related Images

enterin-logo.jpg
Enterin Logo

SOURCE Enterin Inc.

---

Show All News | Disclaimer | Report Violation